首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Improved antimicrobial activity of DU-6859a a new fluoroquinolone against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.
【2h】

Improved antimicrobial activity of DU-6859a a new fluoroquinolone against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.

机译:新型氟喹诺酮类药物DU-6859a对喹诺酮类耐药性肺炎克雷伯菌和阴沟肠杆菌分离株具有增强的抗菌活性并改变了GyrA和ParC蛋白。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MICs of DU-6859a, a novel fluoroquinolone, for 18 Klebsiella pneumoniae isolates and 21 Enterobacter cloacae isolates with altered GyrA or altered GyrA and ParC ranged from < or =0.025 to 6.25 microg/ml and from 0.1 to 3.13 microg/ml, respectively. Based on the MICs at which 90% of the isolates were inhibited for these strains of K. pneumoniae and E. cloacae, DU-6859a exhibited 16- to 256-fold-greater activity than currently available fluoroquinolones.
机译:DU-6859a(一种新颖的氟喹诺酮)对18株肺炎克雷伯菌和GylA改变或GyrA和ParC改变的21株阴沟肠杆菌的MIC分别为<或= 0.025至6.25 microg / ml和0.1至3.13 microg / ml。根据MIC对这些肺炎克雷伯菌和阴沟肠杆菌菌株的抑制率达到90%,与目前可用的氟喹诺酮类药物相比,DU-6859a的活性高出16至256倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号